The Leidos Biomedical Research, Inc.'s staff of scientific, technical, and support professionals conducts basic and applied research in cancer and AIDS. It operates and manages the federal government's only vaccine manufacturing facilities (VPP, BDP), and runs the high-performance Advanced Biomedical Computing Center. It also operates the Frederick National Laboratory for Cancer Research, a Federally Funded Research and Development Center focused on cancer and AIDS research. The Leidos Biomedical Research Biospecimen Research Group (BRG) supports The National Cancer Institute’s (NCI) Biorepositories and Biospecimen Research Branch (BBRB) and is jointly responsible for developing a common biorepository infrastructure that promotes resource sharing and team science, in order to facilitate multi-institutional, high throughput genomic and proteomic studies. The BRG supports a new Biobank project funded through the National Cancer Institute Cancer MoonshotSM Program. The Biobank project will serve the scientific needs of research projects funded by NCI. The biobank will acquire and perform quality control and distribution of clinically-annotated pre- and post-treatment tumor and blood biospecimens from a broad range of adult and young adult patients, including longitudinal samples. The BRG also supports work being performed for the NCI’s Center for Strategic Scientific Initiatives (CSSI), specifically the Clinical Proteomic Tumor Analysis Consortium (CPTAC), a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer with the primary goal to improve the ability to diagnose, treat and prevent cancer by systematically identifying proteins that derive from alterations in cancer genomes and related biological processes, and provide this data with accompanying assays and protocols to the public.
The Biospecimen Research Group supports the NCI by providing excellence in the scientific design and implementation of programs that depend upon the collection of tissue from cancer patients as well as in the management of the data that is collected and ascertained as a result of the research process.
- Directs and controls the activities of the pathology program. Directs specialized pathology research services, including molecular pathology and digital imaging. Plans, conducts, and evaluates a large, complex, multidisciplinary Pathology program
- Performs managerial, administrative and other duties relating to program operations including staffing, procurement, and budgeting
- Supports a wide variety of research activities within the NCI with a major focus on studies of functional genomics and disease mechanisms utilizing genetic approaches, particularly transgenic and gene-targeted mice. Techniques may include gene expression, in situ hybridization, mutational analysis, laser capture microdissection and proteomics. Provides consultative services to the Principal investigators within NCI and Leidos Biomed
- Contributes to experimental design discussions, as well as operational flows
- Reviews histopathology slides or their digital images for tumor content, necrosis and other required features
- Works with human patient tumor images and data with the possibility of communicating results back to the patient.
- Documents findings in pathology reports
- Reviews research protocols regarding safety and clinical efficacy
- Reviews and writes required Standard Operating Procedures utilizing Federal Mandated Standards
- Evaluates and recommends appropriate actions to ensure the Program's quality meets required standards.
- Works with other pathologists, the National Cancer Institute, and with project managers as needed
- Reviews CLIA certified reports as needed
To be considered for this position, you must minimally meet the knowledge, skills, and abilities listed below:
- Possession of a Doctor of Medicine (MD) degree from an accredited college or university according to the Council for Higher Education Accreditation
- Will be required to obtain State of Maryland medical license once offer is accepted
- Completion of medical residency and/or fellowship in applicable specialty area
- American Board of Pathology certification in Anatomic Pathology
- Foreign degrees must be evaluated for U.S. equivalency
- In addition to education requirements, three (3) years of experience in molecular pathology related work
- Background working with federally-regulated research grants, clinical trials, or pharmaceutical projects
- Possess a working knowledge of ICH Good Clinical Practices
- Possess a strong medical background with an interest in cancer research
- Possess excellent written and verbal communication skills
- Must be able to obtain and maintain a security clearance
Candidates with these desired skills will be given preferential consideration:
- American Board of Pathology certification in Clinical Pathology and/or Molecular Pathology.
Leidos is a global science and technology solutions leader working to solve the world’s toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company’s 33,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported pro forma annual revenues of approximately $10 billion for the fiscal year ended January 1, 2016 after giving effect to the recently completed combination of Leidos with Lockheed Martin's Information Systems & Global Solutions business (IS&GS). For more information, visit www.Leidos.com. The company’s diverse employees support vital missions for government and commercial customers. Qualified women, minorities, individuals with disabilities and protected veterans are encouraged to apply. Leidos will consider qualified applicants with criminal histories for employment in accordance with relevant Laws. Leidos is an Equal Opportunity Employer.